Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107003 | 0.85 | GCK (0.57) | GCK | |
| SCHEMBL9105927 | 0.83 | GCK (0.45) | GCKALDH1A1LMNAKDM4ENPC1 | |
| SCHEMBL9908083 | 0.83 | SMN1; SMN2 (0.39) | GCKSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL9908114 | 0.82 | NPC1 (0.47) | GCKSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL9908111 | 0.82 | NPC1 (0.46) | GCKSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL9106900 | 0.82 | KDM4E (0.44) | GCKKDM4ENPC1RAB9AMAPT | |
| SCHEMBL9908079 | 0.82 | KDM4E (0.44) | GCKKDM4ENPC1RAB9AMAPT | |
| SCHEMBL9908103 | 0.78 | GCK (0.43) | GCKSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL9101953 | 0.78 | GCK (0.66) | GCKALDH1A1LMNANPC1RAB9A | |
| SCHEMBL9908097 | 0.78 | GCK (0.42) | GCKSMN1; SMN2ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | GCK 488/4885SMN1; SMN2 1483/4885ALDH1A1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.